000			02298cam a2200349 a 4500
003			EG-GiCUC
005			20250223031732.0
008			170614s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2016.Do.B
100	0		_aDoaa Mahmoud Abdelhamid Garhy
245	1	0	_aBiopharmaceutical study on selected improved carvedilol formulae in a certain dosage form / _cDoaa Mahmoud Abdelhamid Garhy ;supervised Mahmoud M. Ghorab , Howaida K. Ibrahim , Soha A. Ismail
246	1	5	_aدراسة بيوصيدلية لأشكال معدلة ومختارة من عقار الكارفيديلول فى شكل معين
260			_aCairo : _bDoaa Mahmoud Abdelhamid Garhy , _c2016
300			_a182 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aNovel drug delivery dosage forms can provide improved benefits as enhancement in bioavailability, reduction of adverse effects and economic benefits. Elderly people may experience deterioration in their physiological and physical abilities which may lead to encountering difficulties in taking conventional dosage forms due to dysphagia. Carvedilol is Ü1/ non-cardioselective Ý-blocker that is used in the treatment of hypertension and many cardiovascular disorders. It is insoluble in water, intestinal fluids and gastric fluids that undergoes extensive first pass effect and has oral bioavailability of only 25-35%. Therefore, the aim of this thesis is to enhance the bioavailability through preparation of carvedilol nanoparticles to enhance dissolution and so absorption. Also, incorporation of the prepared nanoparticles in a gel form for buccal application to bypass the first pass effect and enhance the bioavailability
530			_aIssued also as CD
653		4	_aCarvedilol formulae
653		4	_aCertain dosage form
653		4	_aPharmaceutics
700	0		_aHowaida K. Ibrahim , _eSupervisor
700	0		_aMahmoud M. Ghorab , _eSupervisor
700	0		_aSoha A. Ismail , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c61216 _d61216